Establishing the Gold Standard for Psychedelic Retreats
The psychedelic therapy landscape is rapidly evolving, with hundreds of psychedelic retreats for mental health emerging worldwide. Yet, it can be challenging to distinguish between what each offers, what makes them unique, why one is better suited for a person than another, and what sets the best ones apart.
Among all the options, MycoMeditations stands apart as the most data-backed psychedelic retreat experience available for addressing mental health challenges.
Through years of rigorous peer-reviewed data collection and comprehensive, third-party verified outcome tracking, MycoMeditations has established itself as the gold standard for evidence-based psychedelic retreats.
This comprehensive analysis examines what makes our program unique, not only in the psychedelic retreat space but within the legal psilocybin therapy space in general. From our groundbreaking quantity and duration of data collection to the superior clinical outcomes experienced by our guests who attend, our psychedelic retreats offer a unique blend of immersion into a natural retreat setting with a clinical rigor not found anywhere else.
We invite you to explore how our approach compares to leading clinical trials and how our model represents the future of psychedelic-assisted therapy.
Data-Backed Psychedelic Retreats: Why Evidence Matters in Healing
Most psychedelic retreats for mental health rely on anecdotal testimonials and subjective experiences to demonstrate their effectiveness. While personal stories hold value and we have plenty of them to share, they don’t provide the scientific rigor necessary to validate treatment outcomes.
Many years ago, MycoMeditations decided to take a fundamentally different approach to sharing the results of our retreat. We aimed to bring as much clinical rigor as possible into a non-clinical environment and utilize data to showcase the outcomes of guests who joined us.
As the only retreat center to systematically track guest outcomes using clinically validated mental health scales over many years, MycoMeditations has collected unprecedented data on long-term outcomes of psilocybin therapy. Our longitudinal surveys utilize standardized assessment tools, including the Patient Health Questionnaire (PHQ-9) for depression, generalized anxiety disorder scale (GAD-7) for generalized anxiety, Severity Measure for Social Anxiety Disorder (SM-SAD-10-Adult) for social anxiety, and the PTSD Checklist (PCL-5) for PTSD.
This commitment to evidence-based psychedelic retreats sets MycoMeditations apart from all other retreat centers that operate without systematic outcome measurement. The result is a comprehensive dataset spanning over many years, highlighting group psychedelic therapy outcomes that match and often exceed those found in clinical research settings.
MycoMeditations Psilocybin Retreat Compared to Psychedelic Clinical Research Studies
The outcomes achieved by our evidence-based psychedelic retreats are shown to consistently match or exceed those reported in leading clinical trials within psychedelic therapy. This is particularly noteworthy, given the substantial capital investment into clinical research and the perceived credibility of a controlled laboratory environment.
Depression Results Exceeding Compass Pathways
We offer an ideal psilocybin retreat option for depression. In our data for the treatment of depression, MycoMeditations guests experienced a 59.60% reduction in symptoms one month post-retreat, compared to Compass Pathways’ Phase 2 clinical trial, which showed a 37.62% reduction three weeks after treatment. The MycoMeditations baseline PHQ-9 score of 15.84 dropped to 6.40 one month post-retreat among 121 participants, while Compass Pathways’ study showed MADRS scores declining from 31.9 to 19.9 among 79 participants.
A Psilocybin Retreat for PTSD Offers Outcomes Comparable to MAPS MDMA Research
When it comes to using psilocybin for PTSD treatment, MycoMeditations achieved results comparable to the renowned Multidisciplinary Association for Psychedelic Studies (MAPS) clinical trials using MDMA. At three months post-retreat, MycoMeditations data showed a 52.7% reduction in PCL-5 scores (from 44.1 to 20.9), closely matching MAPS’ CAPS-5 results showing a 55.5% reduction (from 44.0 to 19.6) after 18 weeks.
First-of-Its-Kind Data on Psilocybin Retreats for Anxiety Disorders
MycoMeditations provides some of the first comprehensive long-term data on psilocybin therapy for generalized anxiety and social anxiety. Our data on psilocybin for generalized anxiety disorder (GAD) showed a 66.7% reduction in GAD-7 scores one month post-retreat (from 14.97 to 4.98). Additionally, our psilocybin treatment for social anxiety disorder (SAD) demonstrated a 72.8% reduction in SM-SAD-10 scores (from 25.44 to 6.91).
Larger Sample Sizes than Psychedelic Clinical Trials
The statistical power of MycoMeditations’ data is further demonstrated by our substantial sample sizes, which span a full year of post-retreat monitoring and consistently exceed those found in many clinical trials.
Every guest who submits a baseline response to MycoMeditations receives requests for follow-up data input in the months that follow their retreat. Only guests who are shown to have a minimum of moderate levels of depression, generalized anxiety, social anxiety, or PTSD—as determined by the standardized assessment tool used for that condition—are included in the dataset.
Our baseline datasets provide a solid foundation for comparing the short-, medium-, and long-term effects of psilocybin therapy at MycoMeditations. Our baseline datasets consist of 241 respondents for depression, 216 for generalized anxiety, 164 for PTSD, and 99 for social anxiety.
It’s important to note that these responses are entirely voluntary for our guests. The decline in responses at each follow-up stage is expected as time passes. Yet, we maintain objectively high comparison numbers at each post-retreat stage when compared to clinical research.
At multiple post-retreat follow-up intervals, our data remains extensive:
- 1 month: 112 respondents for depression, 94 for generalized anxiety, 62 for PTSD, and 51 for social anxiety.
- 3 months: the sample sizes remain strong, with 89 respondents for depression, 75 for generalized anxiety, 49 for PTSD, and 36 for social anxiety.
- 6 months: our datasets hold significant value with 65 respondents for depression, 54 for generalized anxiety, 42 for PTSD, and 30 for social anxiety.
- 12 months: we maintain robust sample sizes: 48 respondents for depression, 41 for generalized anxiety, 28 for PTSD, and 18 for social anxiety.
These large sample sizes provide greater statistical confidence in our findings compared to small clinical trials. For context, many psychedelic clinical trials involve only 20-50 participants studied within shorter periods, making MycoMeditations’ datasets some of the largest and most comprehensive real-world collections of long-term psilocybin therapy outcomes.
Our commitment to gathering data at multiple intervals ensures a deeper understanding of the long-term effects of psychedelics, providing a level of insight not yet seen in traditional clinical psychedelic research.
Pioneering Research on Long-Term Psilocybin Therapy Outcomes
One of MycoMeditations’ most significant contributions to psychedelic research is the comprehensive long-term data on group psychedelic therapy outcomes that we possess. While most clinical trials examine outcomes only weeks or months after treatment, MycoMeditations tracks guest progress for a whole year following the retreat. This also makes us the most data-backed psychedelic retreat.
Our data demonstrates sustained therapeutic benefits across all conditions following the psilocybin therapy sessions at our retreat when compared to baseline symptoms:
- Depression: 50.8% reduction maintained at one year
- Generalized anxiety: 57.8% reduction maintained at one year
- Social anxiety: 53.3% reduction maintained at one year
- PTSD: 51.8% reduction maintained at one year
This long-term data is particularly valuable because it addresses a critical gap in psychedelic research. Few clinical psychedelic studies examine outcomes beyond six months as primary timepoints, making MycoMeditations’ year-long tracking uniquely comprehensive. We can safely say that our data-backed psychedelic retreats offer the potential of long-term healing.
Multiple Psilocybin Therapy Sessions in One Week for the Best Outcomes
MycoMeditations’ data-backed psychedelic retreat differs significantly from clinical trial approaches, yet we are shown to achieve better long-term psilocybin therapy outcomes. While most clinical trials utilize single high-dose sessions with weeks or months between treatments, MycoMeditations provides three, individualized psilocybin therapy sessions within one week, spaced on alternating days.
This intensive protocol, combined with comprehensive preparation and integration support, appears to optimize therapeutic outcomes. The rapid succession of sessions, supported by trained therapists and intensive group integration work, likely accelerates the healing processes that take place within our guests. We have found this to be ideal for achieving the best group psychedelic therapy outcomes.
Our Data-Backed Psychedelic Retreat is Designed for Real-World Populations
Unlike clinical trials that carefully screen participants to exclude comorbid conditions, MycoMeditations assists guests with complex, real-world mental health presentations, where comorbidities are common. Our guests frequently experience multiple conditions simultaneously—depression with anxiety, PTSD with substance use concerns, or various combinations of mental health challenges. For instance, it is common for people to seek out a psilocybin retreat for anxiety and PTSD, as these conditions often arise together.
This population at our psychedelic retreats represents a more accurate reflection of the individuals within the societal mainstream who will eventually be seeking psychedelic therapy once legalization occurs. The fact that MycoMeditations achieves significant, positive outcomes within this complex population demonstrates the robustness and real-world applicability of our psychedelic retreat for mental health.
Psilocybin Therapy Dosing Protocols Optimized for Individual Needs
MycoMeditations employs advanced dosing protocols that differ from the standardized approaches used in clinical trials. While research studies typically use fixed doses regardless of any personal factors—which is understandable for the sake of clinical research—MycoMeditations chooses to tailor dosing for each guest’s psilocybin therapy session to account for numerous physical and psychological factors.
Below are our escalating dose protocol averages shown in the data across the four mental health conditions that were analyzed:
- Session 1: 3.5-3.7 grams dried Psilocybe cubensis
- Session 2: 6.5-7.0 grams dried Psilocybe cubensis
- Session 3: 8.1-8.9 grams dried Psilocybe cubensis
Converting these whole mushroom doses to pure psilocybin equivalents (using the moderate potency B+ strain of Psilocybe cubensis, which averages approximately 1% of pure psilocybin per gram of dried Psilocybe cubensis), MycoMeditations’ sessions deliver roughly:
- Session 1: 35-37mg pure psilocybin equivalent
- Session 2: 65-70mg pure psilocybin equivalent
- Session 3: 81-89mg pure psilocybin equivalent
These doses exceed the typical 25mg high-dose standard used in psilocybin clinical trials, potentially contributing to the often superior outcomes experienced by MycoMeditations’ guests. We believe that an evidence-based psychedelic retreat should offer protocols shown to be effective, rather than rigidly stick to protocols in clinical trials that may not be optimal.
A Truly Unique Data-Backed Psychedelic Retreat
The MycoMeditations psychedelic retreat methodology represents another optimal differentiation from other legal psilocybin retreats and the clinical world of psilocybin therapy research.
While clinical trials focus on individual participants, MycoMeditations facilitates group experiences with up to 10 guests supported by trained licensed therapists and facilitators. This is also what differentiates MycoMeditations from other psychedelic retreats, which have less therapeutic emphasis and support available from licensed mental health professionals.
Our facilitator-to-guest ratio of at least 1:1.5 ensures personalized attention while maintaining the valuable benefits of group work amongst the retreat guests. This also gives MycoMeditations a unique flexibility to offer private psilocybin therapy sessions, as done in clinical trials. This contrasts with the typical scenario at other psychedelic retreats, where guests gather in a circle for the ceremony while a small number of facilitators (or shamans) guide the session.
Over many years of operation and data collection, this psychedelic retreat approach has been shown to consistently produce clinically significant outcomes that match or surpass the clinical trials of psychedelic therapy. We have some of the best group psychedelic therapy outcomes.
Our Psychedelic Retreat for Mental Health Meets Strong Safety and Professional Standards
MycoMeditations operates under rigorous safety protocols that match or exceed clinical standards. Our team includes trained psychedelic therapists, medical professionals, and experienced facilitators who ensure safe, supportive experiences for all guests.
Each therapist and facilitator staffed by MycoMeditations completes six retreats of what we call “Facilitator in Training”. This training role allows new facilitators to gradually learn from more experienced team members while serving in an observational capacity. They learn through shadowing to understand how MycoMeditations psilocybin therapists and facilitators effectively work with a variety of guests, both during the psilocybin sessions, within integration, and during retreat downtime.
The MycoMeditations Facilitator-in-Training role involves training across 18 actual legal psilocybin therapy sessions—approximating 100 hours—which greatly surpasses the practicum training required by State licensing bodies, such as in Oregon or Colorado. Our team receives significantly more direct training with psilocybin than what’s offered by any of the psychedelic facilitator training programs available at organizations such as Fluence, Innertrek, SoundMind, Synthesis Institute, or the California Institute of Integral Studies (CIIS).
The retreat’s location in Jamaica also provides access to completely legal psilocybin therapy, eliminating the legal complexities that can complicate psychedelic treatment in other jurisdictions.
Comprehensive and Evidence-Based Psychedelic Retreat Programs
The MycoMeditations model extends far beyond simply offering three psilocybin sessions to produce the positive results shown in our data. Our comprehensive, data-backed psychedelic retreat program includes:
Pre-Retreat Preparation
- Thorough medical and psychological screening
- Preparation call with a MycoMeditations therapist
- Materials to best prepare for the retreat experience
- Activities and exercises to explore
- Recommended reading
- Curated music suggestions for the psilocybin therapy sessions
During-Retreat Therapeutic Support
- Three private psilocybin therapy sessions
- Extensive preparation sessions before every dose
- Psychoeducation about the psilocybin experience and all relevant psychological and spiritual aspects to healing
- Pre-session mediation
- Extensive group psychedelic integration sessions
- Individual therapy sessions as needed
- 24/7 psychological, medical, and hospitality support
Post-Retreat Integration
- Three group integration sessions via Zoom
- Bi-weekly integration sessions open to all alumni
- Options for private integration with our therapists
- Introduction to a vetted network of private psychedelic integration specialists
- Long-term outcome tracking
This comprehensive psychedelic retreat program, which is specialized for the therapeutic use of psilocybin, is what contributes to the sustained benefits observed in MycoMeditations’ long-term data.
Limitations and Transparency
MycoMeditations maintains transparency regarding our data collection methods, acknowledging that these surveys do not constitute formal clinical trials. While this data lacks the controlled conditions of academic research, it offers valuable insights into the efficacy of psychedelic therapy in the real world.
To ensure the accuracy of our data collection, we partnered with a third-party academic institution specializing in psychedelic research to verify these findings. Our commitment to scientific rigor, combined with our substantial dataset, provides confidence in our reported mental health outcomes. We do not claim that a data-backed psychedelic retreat guarantees psychological healing in all cases. However, the quality of the data does make MycoMeditations the gold standard in psychedelic retreats for mental health.
To read the full report of each dataset that this article examined, you may click the links below:
Additional Research on the Benefits of Psilocybin Retreats
A wide range of evidence informs our data-backed psychedelic retreat. We can look beyond our own data collection to the scientific literature, and here we also find promising results. Other research shows that psilocybin retreats offer myriad benefits, encompassing much more than the alleviation of psychological distress.
A 2019 study published in the Journal of Psychoactive Drugs found that a psilocybin retreat led participants to experience increases in empathy, creativity, and well-being. In addition, a 2022 study published in Frontiers in Psychiatry demonstrated that taking psilocybin in a retreat setting can lead to:
- Reductions in anxiety
- Reductions in depression
- Reductions in neuroticism
- Increases in mindfulness
- Enhanced connectedness to oneself and others
- Mystical experiences
- Emotional insight
While there are differences between clinical trials on psilocybin-assisted therapy and psilocybin retreats, it’s becoming clear that a data-backed psychedelic retreat can powerfully transform people’s lives.
The Future of Evidence-Based Psychedelic Retreats
MycoMeditations represents a new paradigm of psilocybin therapy within a psychedelic retreat setting—one that combines the accessibility and holistic approach of retreat settings with the rigor and accountability of clinical research. The evidence highlighted in this article demonstrates that a data-backed psychedelic retreat can be equally or more effective than legal psilocybin therapy offered in a clinical setting.
As the psychedelic therapy field continues to evolve, MycoMeditations’ pioneering approach offers a blueprint for how psychedelic retreat centers can contribute meaningfully to our understanding of these powerful medicines. We remain committed to data collection, outcome tracking, and scientific transparency, setting the standard for psychedelic retreats with our data-backed outcomes.
By MycoMeditations
Summary of Treating Depression with Psilocybin at MycoMeditations
- The MycoMeditations psilocybin-assisted retreat model shows comparable positive outcomes for the treatment of depression as found within clinical research.
- MycoMeditations survey data shows better outcomes than biopharmaceutical company Compass Pathways in their Phase 2 studies of their proprietary psilocybin analog one month after psilocybin session(s) in Major Depressive Disorder.
- Clinically significant improvements in depression maintained one year following retreat.
- Support for multiple, short-term psilocybin doses; potential for unique psilocybin-assisted treatment protocols.
- Data supports the need for tailored dosing on numerous physical and mental factors rather than standardized dosing based on bodyweight.
- Psilocybin in group therapeutic retreat settings may be a viable treatment for depression when supported with individual therapy.
MycoMeditations is proud to share these results in order to further demonstrate the validity and safety of psychedelic-assisted therapy in naturalistic contexts and retreat settings. The MycoMeditations retreat model demonstrably provides comparable levels of positive, lasting outcomes when compared to clinical settings for psychedelic-assisted therapy and clinical trials.
One month after retreat, MycoMeditations clients (n = 121) experienced 59.60% reduction in depression symptoms (15.84 at baseline to 6.40 one month post-retreat). In the research summary for Compass Pathways’ Phase 2 psilocybin analog study, participants (n = 79) experienced 37.62% reduction in symptoms three weeks after treatment, where least-squares mean changes from baseline to week three were −12.0 on the MADRS (31.9 to 19.9).
Retreat outcomes remained clinically significant one year after the retreat experience, indicating sustained effectiveness in the MycoMeditations psilocybin-assisted retreat model to treat depression. Few psilocybin clinical trials examine outcomes this far from treatment, which advocates for the long-term efficacy of psilocybin in general.
The survey outcomes highlight the benefit of three psilocybin sessions within one week when supported by trained psychedelic-assisted therapists during sessions and integration. The matching efficacy of multiple, short-term psilocybin sessions when compared to single treatments with prolonged periods between sessions as shown in clinical research indicates the safety, viability, and flexibility for varying courses of psilocybin-related treatments. This advocates for custom treatment options depending on unique patient needs.
MycoMeditations dosing protocols take into account numerous factors when determining the ideal psilocybin dose for a client. The optimal dose for each person varies significantly, and the MycoMeditations protocol realizes the need for a tailored approach to dosing in order to maximize benefits.
This data also emphasizes the utility of group psychedelic-assisted therapy, as MycoMeditations retreats are group experiences with up to 12 people assisted by therapists, with a typical facilitator-to-client ratio of at least 1:1.5, team to guests.
Population: Real-World Clients
MycoMeditations clients involved in this survey, while seeking therapeutic outcomes for depression, often live with comorbid conditions such as anxiety, PTSD, OCD, substance use disorder, other forms of addiction, and other mental illnesses.
This population more accurately reflects individuals living with mental health conditions who may benefit from therapeutic intervention, compared to the participant cohorts of many clinical trials, in which comorbidities are often screened out.
Preparation, Dosing, and Integration Protocols
The optional surveys were completed by clients enrolling in the seven-day psilocybin-assisted retreat program at MycoMeditations, where they received preparation for their psilocybin sessions, three dosing sessions spaced on alternating days, and group integration on the days between each dosing session. After the retreats had concluded, clients were also encouraged to participate in two group integration sessions via Zoom.
Clients were administered dried Psilocybe cubensis, which is cultivated on-site and encapsulated into 0.5g capsules. MycoMeditations’ dosing regimen is standardized around the use of encapsulated psilocybin mushrooms with an escalating dosing protocol over the course of the three (3) sessions. The dose for Session 1 is virtually identical for all clients, however, the MycoMeditations protocol takes many physical and mental factors into account when determining the ideal dose for Session 2 and Session 3, as a tailored dosing method was found to be most beneficial.
The average dose in dried, encapsulated grams of psilocybin mushrooms from Session 1 has an average SD of 3.71 ± 1.06. Session 2 has an average SD of 7.00 ± 1.73 and Session 3 has an average SD of 8.97 ± 3.33. The total dose over the duration of the retreat has an average SD of 19.67 ± 5.28.
Results for the Treatment of Depression at MycoMeditations Psilocybin Retreats
The depression dataset was examined using the PHQ-9 rating scale. A PHQ-9 minimum score of 10 (considered moderate levels of depression) was selected as inclusion criteria for a baseline response to be included in the dataset. The baseline results included 241 participants.
The baseline dataset, verified by a third-party source, determined that people living with moderate to extreme levels of depression (average PHQ-9 score of 15.84) experienced clinically significant reductions in symptoms at the below time points following the retreat, with average PHQ-9 scores along with percentage changes in symptoms relative to baseline and sample size (n) shown below:
The data presented here do not account for a number of post-retreat lifestyle factors, including therapeutic support and approach to self-care undertaken by clients once back at home. Some clients did not complete or have not reached all follow-up assessment time points. MycoMeditations is continually exploring ways to support the ongoing therapeutic treatment of its clients and always recommends full follow-up and integration procedures as well as continual, conventional mental health support and care in order to ensure the best long-term psychological outcomes.
Survey Set-Up Details
These longitudinal surveys assess the long-term outcomes of guests who attend psilocybin-assisted retreats offered by MycoMeditations in Jamaica.
MycoMeditations’ longitudinal surveys are not and do not attempt to constitute either an academic study or a registered clinical trial in their procedure, structure, or review process. However, insights drawn from this data convey a need for additional research into the mental health therapeutic benefits of psilocybin and points toward efficacy of treatment models outside of standard clinical and laboratory contexts. All data shared by MycoMeditations was analyzed and verified by a third-party academic partner.
This report shares the retreat outcomes in guests who joined us to overcome depression that contributed to our longitudinal surveys over the course of a year following their retreat.
MycoMeditations’ psilocybin-assisted retreat model led to clinically significant outcomes in the treatment of depression according to client surveys. These results also suggested long-term efficacy, with significant positive results remaining one year after the retreat experience.
All data represented here was collected between July 2021 and December 2024 with the consent of MycoMeditations clients.
Review our Guest Outcomes for Other Conditions
Psilocybin Retreat Outcomes for Depression
Summary of Treating Generalized Anxiety with Psilocybin at MycoMeditations
- MycoMeditations survey reveals one of the first samples of long-term data revealing efficacy for psilocybin-assisted therapy in assisting with generalized anxiety.
- Clinically significant improvements in generalized anxiety maintained one year following retreat.
- Support for multiple, short-term psilocybin doses; potential for unique psilocybin-assisted treatment protocols.
- Data supports the need for tailored dosing on numerous physical and mental factors rather than standardized dosing based on bodyweight.
- Psilocybin in group therapeutic retreat settings may be a viable treatment for generalized anxiety when supported with individual therapy.
Clinical trials examining the effects of psilocybin on generalized anxiety are limited in number. MycoMeditations surveys reveal first-of-its-kind outcomes in the fight against anxiety disorders with psilocybin.
Retreat outcomes remained clinically significant one year after the retreat experience, indicating effectiveness in the MycoMeditations psilocybin-assisted retreat model in treating generalized anxiety. Few psilocybin clinical trials examine outcomes this far from treatment, which advocates for the long-term efficacy of psilocybin in general.
The survey outcomes highlight the benefit of three psilocybin sessions within one week when supported by trained psychedelic-assisted therapists during sessions and integration. The matching efficacy of multiple, short-term psilocybin sessions when compared to single treatments with prolonged periods between sessions as shown in clinical research indicates the safety, viability, and flexibility for varying courses of psilocybin-related treatments. This advocates for custom treatment options depending on unique patient needs.
MycoMeditations dosing protocols take into account numerous factors when determining the ideal psilocybin dose for a client. The optimal dose for each person varies significantly, and the MycoMeditations protocol realizes the need for a tailored approach to dosing in order to maximize benefits.
This data also emphasizes the utility of group psychedelic-assisted therapy, as MycoMeditations retreats are group experiences with up to 12 people assisted by therapists, with a typical facilitator-to-client ratio of at least 1:1.5, team to guests.
Population: Real-World Clients
MycoMeditations clients involved in this survey, while seeking therapeutic outcomes for generalized anxiety, often live with comorbid conditions such as other forms of anxiety, depression, PTSD, OCD, substance use disorder, other forms of addiction, and other mental illnesses.
This population more accurately reflects individuals living with mental health conditions who may benefit from therapeutic intervention, compared to the participant cohorts of many clinical trials, in which comorbidities are often screened out.
Preparation, Dosing, and Integration Protocols
The optional surveys were completed by clients enrolling in the seven-day psilocybin-assisted retreat program at MycoMeditations, where they received preparation for their psilocybin sessions, three dosing sessions spaced on alternating days, and group integration on the days between each dosing session. After the retreats had concluded, clients were also encouraged to participate in two group integration sessions via Zoom.
Clients were administered dried Psilocybe cubensis, which is cultivated on-site and encapsulated into 0.5g capsules. MycoMeditations’ dosing regimen is standardized around the use of encapsulated psilocybin mushrooms with an escalating dosing protocol over the course of the three (3) sessions. The dose for Session 1 is virtually identical for all clients, however, the MycoMeditations protocol takes many physical and mental factors into account when determining the ideal dose for Session 2 and Session 3, as a tailored dosing method was found to be most beneficial.
The average dose in dried, encapsulated grams of psilocybin mushrooms from Session 1 has an average SD of 3.52 ± 0.92. Session 2 has an average SD of 6.54 ± 1.45 and Session 3 has an average SD of 8.43 ± 3.02. The total dose over the duration of the retreat has an average SD of 18.49 ± 4.38.
Results for the Treatment of Generalized Anxiety at MycoMeditations Psilocybin Retreats
The generalized anxiety dataset was examined using the GAD-7 rating scale. A GAD-7 minimum score of 10 (considered moderate levels of generalized anxiety) was selected as inclusion criteria for a baseline response to be included in the dataset. The baseline results included 216 participants.
The baseline dataset, verified by a third-party source, determined that people living with moderate to extreme levels of generalized anxiety (average GAD-7 score of 14.97) experienced clinically significant reductions in symptoms at the below time points following the retreat, with average GAD-7 scores along with percentage changes in symptoms relative to baseline and sample size (n) shown below:
The data presented here do not account for a number of post-retreat lifestyle factors, including therapeutic support and approach to self-care undertaken by clients once back at home. Some clients did not complete or have not reached all follow-up assessment time points. MycoMeditations is continually exploring ways to support the ongoing therapeutic treatment of its clients and always recommends full follow-up and integration procedures as well as continual, conventional mental health support and care in order to ensure the best long-term psychological outcomes.
Survey Set-Up Details
These longitudinal surveys assess the long-term outcomes of guests who attend psilocybin-assisted retreats offered by MycoMeditations in Jamaica.
MycoMeditations’ longitudinal surveys are not and do not attempt to constitute either an academic study or a registered clinical trial in their procedure, structure, or review process. However, insights drawn from this data convey a need for additional research into the mental health therapeutic benefits of psilocybin and points toward efficacy of treatment models outside of standard clinical and laboratory contexts. All data shared by MycoMeditations was analyzed and verified by a third-party academic partner.
This report shares the retreat outcomes in guests who joined us to overcome generalized anxiety that contributed to our longitudinal surveys over the course of a year following their retreat.
MycoMeditations’ psilocybin-assisted retreat model led to clinically significant outcomes in the treatment of generalized anxiety according to client surveys. These results also suggested long-term efficacy, with significant positive results remaining one year after the retreat experience.
All data represented here was collected between July 2021 and December 2024 with the consent of MycoMeditations clients.
Review our Guest Outcomes for Other Conditions
Psilocybin Retreat Outcomes for Generalized Anxiety
By MycoMeditations
Summary of Treating Social Anxiety with Psilocybin at MycoMeditations
- MycoMeditations survey reveals one of the first samples of long-term data revealing efficacy for psilocybin-assisted therapy in assisting with social anxiety.
- Clinically significant improvements in social anxiety maintained one year following retreat.
- Support for multiple, short-term psilocybin doses; potential for unique psilocybin-assisted treatment protocols.
- Data supports the need for tailored dosing on numerous physical and mental factors rather than standardized dosing based on bodyweight.
- Psilocybin in group therapeutic retreat settings may be a viable treatment for social anxiety when supported with individual therapy.
Clinical trials examining the effects of psilocybin on social anxiety are limited in number. MycoMeditations surveys reveal first-of-its-kind outcomes in the fight against anxiety disorders with psilocybin.
Retreat outcomes remained clinically significant one year after the retreat experience, indicating effectiveness in the MycoMeditations psilocybin-assisted retreat model for treating social anxiety. Few psilocybin clinical trials examine outcomes this far from treatment, which advocates for the long-term efficacy of psilocybin in general.
The survey outcomes highlight the benefit of three psilocybin sessions within one week when supported by trained psychedelic-assisted therapists during sessions and integration. The matching efficacy of multiple, short-term psilocybin sessions when compared to single treatments with prolonged periods between sessions as shown in clinical research indicates the safety, viability, and flexibility for varying courses of psilocybin-related treatments. This advocates for custom treatment options depending on unique patient needs.
MycoMeditations dosing protocols take into account numerous factors when determining the ideal psilocybin dose for a client. The optimal dose for each person varies significantly, and the MycoMeditations protocol realizes the need for a tailored approach to dosing in order to maximize benefits.
This data also emphasizes the utility of group psychedelic-assisted therapy, as MycoMeditations retreats are group experiences with up to 12 people assisted by therapists, with a typical facilitator-to-client ratio of at least 1:1.5, team to guests.
Population: Real-World Clients
MycoMeditations clients involved in this survey, while seeking therapeutic outcomes for social anxiety, often live with comorbid conditions such as other forms of anxiety, depression, PTSD, OCD, substance use disorder, other forms of addiction, and other mental illnesses.
This population more accurately reflects individuals living with mental health conditions who may benefit from therapeutic intervention, compared to the participant cohorts of many clinical trials, in which comorbidities are often screened out.
Preparation, Dosing, and Integration Protocols
The optional surveys were completed by clients enrolling in the seven-day psilocybin-assisted retreat program at MycoMeditations, where they received preparation for their psilocybin sessions, three dosing sessions spaced on alternating days, and group integration on the days between each dosing session. After the retreats had concluded, clients were also encouraged to participate in two group integration sessions via Zoom.
Clients were administered dried Psilocybe cubensis, which is cultivated on-site and encapsulated into 0.5g capsules. MycoMeditations’ dosing regimen is standardized around the use of encapsulated psilocybin mushrooms with an escalating dosing protocol over the course of the three (3) sessions. The dose for Session 1 is virtually identical for all clients, however, the MycoMeditations protocol takes many physical and mental factors into account when determining the ideal dose for Session 2 and Session 3, as a tailored dosing method was found to be most beneficial.
The average dose in dried, encapsulated grams of psilocybin mushrooms from Session 1 has an average SD of 3.65 ± 0.84. Session 2 has an average SD of 6.51 ± 1.65 and Session 3 has an average SD of 8.11 ± 3.49. The total dose over the duration of the retreat has an average SD of 18.27 ± 5.11.
Results for the Treatment of Social Anxiety at MycoMeditations Psilocybin Retreats
The social anxiety dataset was examined using the SM-SAD-10-Adult rating scale. A SAD-10 minimum score of 19 (considered moderate levels of social anxiety) was selected as inclusion criteria for a baseline response to be included in the dataset. The baseline results included 90 participants.
The baseline dataset, verified by a third-party source, determined that people living with moderate to extreme levels of social anxiety (average SAD-10 score of 25.44) experienced clinically significant reductions in symptoms at the below timepoints following the retreat, with average SAD-10 scores along with percentage changes in symptoms relative to baseline and sample size (n) shown below:
The data presented here do not account for a number of post-retreat lifestyle factors, including therapeutic support and approach to self-care undertaken by clients once back at home. Some clients did not complete or have not reached all follow-up assessment time points. MycoMeditations is continually exploring ways to support the ongoing therapeutic treatment of its clients and always recommends full follow-up and integration procedures as well as continual, conventional mental health support and care in order to ensure the best long-term psychological outcomes.
Survey Set-Up Details
These longitudinal surveys assess the long-term outcomes of guests who attend psilocybin-assisted retreats offered by MycoMeditations in Jamaica.
MycoMeditations’ longitudinal surveys are not and do not attempt to constitute either an academic study or a registered clinical trial in their procedure, structure, or review process. However, insights drawn from this data convey a need for additional research into the mental health therapeutic benefits of psilocybin and points toward efficacy of treatment models outside of standard clinical and laboratory contexts. All data shared by MycoMeditations was analyzed and verified by a third-party academic partner.
This report shares the retreat outcomes in guests who joined us to overcome social anxiety that contributed to our longitudinal surveys over the course of a year following their retreat.
MycoMeditations’ psilocybin-assisted retreat model led to clinically significant outcomes in the treatment of social anxiety according to client surveys. These results also suggested long-term efficacy, with significant positive results remaining one year after the retreat experience.
All data represented here was collected between July 2021 and December 2024 with the consent of MycoMeditations clients.
Review our Guest Outcomes for Other Conditions
Psilocybin Retreat Outcomes for Social Anxiety
Summary of Treating PTSD with Psilocybin at MycoMeditations
- MycoMeditations results are comparable to the MAPS PBC Phase 3 trial outcomes. MAPS PBC data, utilizing the CAPS-5 scale, showed the baseline score of 44.0 fell to 19.6 (-55.5%) after 18 weeks. At three months post-retreat, MycoMeditations data, utilizing the PCL-5, showed a 52.7% reduction in symptoms between baseline (44.1) and three months post retreat (20.9). This is sustained at six months post-retreat with 53.1% reduction in symptoms, and one year post-retreat with 51.8%.
- MycoMeditations survey reveals one of the first samples of long-term data revealing efficacy for psilocybin-assisted therapy in assisting with PTSD.
- Clinically significant improvements in PTSD maintained one year following retreat.
- Data supports the need for tailored dosing on numerous physical and mental factors rather than standardized dosing based on bodyweight.
- Psilocybin in group therapeutic retreat settings may be a viable treatment for PTSD when supported with individual therapy.
MycoMeditations guest outcome data for treating Post-Traumatic Stress Disorder with psilocybin shows similar results to the Multidisciplinary Association for Psychedelic Studies (MAPS) clinical research trails utilizing MDMA to treat PTSD when comparing results three months after the therapeutic sessions. Guests of MycoMeditations experienced a 52.7% reduction in PTSD symptoms when compared to baseline three months post-retreat (PCL-5 scores dropping from 44.1 to 20.9), whereas MAPS PBC Phase 3 trail outcomes showed symptoms reduction of 55.5% (CAPS-5 scores dropped from 44.0 to 19.6) when measured 18 week post-treatment compared to baseline.
While there is significant data showing MDMA’s effectiveness in treating Post-Traumatic Stress Disorder, clinical trials examining the effects of psilocybin on PTSD are limited in number. MycoMeditations surveys reveal first-of-its-kind outcomes in the fight against PTSD with psilocybin.
Retreat outcomes remained clinically significant one year after the retreat experience, indicating effectiveness in the MycoMeditations psilocybin-assisted retreat model in treating PTSD. Few psilocybin clinical trials examine outcomes this far from treatment, which advocates for the long-term efficacy of psilocybin in general.
MycoMeditations dosing protocols take into account numerous factors when determining the ideal psilocybin dose for a client. The optimal dose for each person varies significantly, and the MycoMeditations protocol realizes the need for a tailored approach to dosing in order to maximize benefits.
This data also emphasizes the utility of group psychedelic-assisted therapy, as MycoMeditations retreats are group experiences with up to 12 people assisted by therapists, with a typical facilitator-to-client ratio of at least 1:1.5, team to guests.
Population: Real-World Clients
MycoMeditations clients involved in this survey, while seeking therapeutic outcomes for PTSD, often live with comorbid conditions such as various forms of depression, anxiety, and/or alcohol use disorder (AUD) or other forms of addiction, among others.
This population more accurately reflects individuals living with mental health conditions who may benefit from therapeutic intervention, compared to the participant cohorts of many clinical trials, in which comorbidities are often screened out.
Preparation, Dosing, and Integration Protocols
The survey, which was optional to participate in, was completed by clients enrolling in the seven-day psilocybin-assisted retreat program at MycoMeditations, where they received preparation for their psilocybin sessions, three dosing sessions spaced on alternating days, and group integration on the days between each dosing session. After the retreats had concluded, clients were also encouraged to participate in two group integration sessions via Zoom.
Clients were administered dried Psilocybe cubensis, which is cultivated on-site and encapsulated into 0.5g capsules. MycoMeditations’ dosing regimen is highly standardized for utilizing whole psilocybin mushrooms with an escalating dosing protocol over the course of the three (3) sessions. The dose for Session 1 is virtually identical for all clients, however, the MycoMeditations protocol takes many physical and mental factors into account when determining the ideal dose for Session 2 and Session 3, as a tailored dosing method was found to be most beneficial.
The average dose in dried, encapsulated grams of psilocybin mushrooms from Session 1 has an average SD of 3.68 ± 1.08. Session 2 has an average SD of 6.76 ± 1.90 and Session 3 has an average SD of 8.51 ± 3.62. The total dose over the duration of the retreat has an average SD of 18.95 ± 5.52.
Results for the Treatment of PTSD at MycoMeditations Psilocybin Retreats
The PTSD dataset was examined using the PCL-5 rating scale. A PCL-5 minimum score of 31 (considered moderate levels of PTSD) was selected as inclusion criteria for a baseline response to be included in the dataset. The baseline results included 164 participants.
The baseline dataset, verified by a third-party source, determined that people living with moderate to extreme levels of PTSD (average PCL-5 score of 44.07) experienced clinically significant reductions in symptoms at the below time points following the retreat, with average PCL-5 scores along with percentage changes in symptoms relative to baseline and sample size (n) shown below:
The data presented here do not account for a number of post-retreat lifestyle factors, including therapeutic support and approach to self-care undertaken by clients once back at home. Some clients did not complete or have not reached all follow-up assessment time points. MycoMeditations is continually exploring ways to support the ongoing therapeutic treatment of its clients and always recommends full follow-up and integration procedures as well as continual, conventional mental health support and care in order to ensure the best long-term psychological outcomes.
Survey Set-Up Details
These longitudinal surveys assess the long-term outcomes of guests who attend psilocybin-assisted retreats offered by MycoMeditations in Jamaica.
MycoMeditations’ longitudinal surveys are not and do not attempt to constitute either an academic study or a registered clinical trial in their procedure, structure, or review process. However, insights drawn from this data convey a need for additional research into the mental health therapeutic benefits of psilocybin and points toward efficacy of treatment models outside of standard clinical and laboratory contexts. All data shared by MycoMeditations was analyzed and verified by a third-party academic partner.
This report shares the retreat outcomes in guests who joined us to overcome PTSD that contributed to our longitudinal surveys over the course of a year following their retreat.
MycoMeditations’ psilocybin-assisted retreat model led to clinically significant outcomes in the treatment of PTSD according to client surveys. These results also suggested long-term efficacy, with significant positive results remaining one year after the retreat experience.
All data represented here was collected between July 2021 and December 2024 with the consent of MycoMeditations clients.
Review the Outcomes for Other Conditions
